Amyotrophic lateral sclerosis: mortality risk during the course of the disease and prognostic factors
Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease of the upper and lower motor neurons (Leigh and Ray-Chaudhuri, 1994). It leads to progressive weakness and severe disability within a few years. The diagnosis usually carries a poor prognosis with a median survival of 1–3 years from diagnosis (Christensen et al., 1990, Norris et al., 1993) and of 2–4 years from initial weakness (Tysnes et al., 1991, Chancellor et al., 1993, Eisen et al., 1993, Haverkamp et al., 1995). The course of the disease is reported to be slowly progressive with a linear decline of muscle strength (Munsat et al., 1988) and a constant risk of death (Christensen et al., 1990, Norris et al., 1993). This is at odds with clinical experience that a substantial proportion of patients survive diagnosis 5 or more years (Mulder and Howard, 1976, Christensen et al., 1990, Norris et al., 1993) and that these patients seems to have a better prognosis than those who have been diagnosed more recently. Furthermore, survival is known to vary considerably and is considered to be difficult to predict in individual cases, but how and why patients differ is not yet clear. Clinical characteristics related to survival probably include age (Juergens et al., 1980, Uebayashi et al., 1983, Kondo and Hemmi, 1984, Caroscio et al., 1987, Jablecki et al., 1989, Christensen et al., 1990, Chancellor et al., 1993, Eisen et al., 1993, Norris et al., 1993, Haverkamp et al., 1995) and site of onset (Mulder and Howard, 1976, Uebayashi et al., 1983, Kondo and Hemmi, 1984, Mortara et al., 1984, Caroscio et al., 1987, Christensen et al., 1990, Chancellor et al., 1993, Norris et al., 1993).
In order to study the mortality risk throughout the disease and identify prognostic factors related to mortality, we performed a historical cohort study of untreated patients with ALS, who were referred to one of the university hospitals in The Netherlands.
Section snippets
Patients
We retrieved the hospital records of consecutive patients who had been diagnosed as having ALS or motor neuron disease between January 1, 1970 and January 1, 1988. All available clinical data were reviewed for confirmation of the diagnosis. Patients who fulfilled the clinical diagnostic criteria for probable or definite ALS (Brooks, 1994) were eligible for the study: upper and lower motor neuron signs; insidious onset and progression of weakness; involvement of at least two body regions
Patients
The study cohort consisted of 307 patients, 170 males and 137 females. We excluded 173 patients, coded under the diagnostic category of ALS or motor neuron disease, but who did not fulfil the clinical diagnostic criteria of probable or definite ALS, including 47 patients with progressive spinal muscular atrophy, one with progressive bulbar palsy, 16 with primary lateral sclerosis, 20 with multisystem atrophy, one with a suspected postpoliomyelitis syndrome, 17 with ALS-mimic syndromes (Louwerse
Discussion
We found that the mortality risk of patients with ALS did not remain constant through the disease. Mortality was at its maximum in the second year after diagnosis and declined considerably thereafter. Patients who survived diagnosis 6 years or more, had almost the same life expectancy as their healthy coevals. In addition, we observed associations between mortality and age at diagnosis, site of onset, and the delay from initial weakness to diagnosis. The better prognosis of patients presenting
Acknowledgements
The authors are indebted to Prof. M. Vermeulen, for advice and support.
References (26)
Markov models of natural history
J. Clin. Epidemiol
(1988)World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis
J. Neurol. Sci
(1994)- et al.
Amyotrophic lateral sclerosis. Its natural history
Neurol. Clin
(1987) - et al.
Motoneurone disease and ageing
Lancet
(1973) - et al.
Motor neuron disease in the province of Turin, Italy, 1966–1980: survival analysis
J. Neurol. Sci
(1984) - et al.
Onset, natural history and outcome in idiopathic motor neuron disease
J. Neurol. Sci
(1993) - et al.
Background mortality in clinical survival studies
Lancet
(1993) - et al.
The prognosis of adult onset motor neuron disease: a prospective study based on the Scottish motor neuron disease register
J. Neurol
(1993) - et al.
ALS in Limousin (Limoges area, France)
Neuroepidemiology
(1986) - et al.
Survival of patients with amyotrophic lateral sclerosis
Neurology
(1990)
Regression models and life tables
J. R. Stat. Soc. B
Duration of amyotrophic lateral sclerosis is age dependent
Muscle Nerve
Amyotrophic lateral sclerosis. A study of its presentation and prognosis
J. Neurol
Cited by (98)
Amyotrophic Lateral Sclerosis and the Respiratory System
2018, Clinics in Chest MedicinePrognostic factors for survival in patients with amyotrophic lateral sclerosis: analysis of a multi-centre clinical trial
2016, Journal of Clinical NeuroscienceCitation Excerpt :Numerous prognostic factors have previously been proposed as predictors of survival in ALS. Clinical factors consistently reported to be associated with a worse outcome include older age at disease onset [2–16], bulbar as opposed to limb onset disease [3–7,10,11,14–17] and a shorter delay between symptom onset and diagnosis [7,8,10,13,15–17]. Other documented factors include respiratory and nutritional status.
Effects of intravenous laser irradiation on respiratory physiology parameters of amyotrophic lateral sclerosis patients: An uncontrolled observational study
2016, European Journal of Integrative MedicineCitation Excerpt :Eighty-four percent of ALS patients die from respiratory complications and respiratory insufficiency within 2–3 years after diagnosis. Thus, the time and degree of progressive respiratory muscle weakness are important factors in determining the prognosis for ALS patients [4,5]. Intravenous laser irradiation (ILI) was originally put forward in the United States in 1982, but it was popularized in Russia in the 1980s and in China in the 1990s [6].
Feasibility assessment of using the MiToS staging system for conducting economic evaluation in amyotrophic lateral sclerosis
2024, Expert Review of Pharmacoeconomics and Outcomes ResearchNeuroprognostication for Patients with Amyotrophic Lateral Sclerosis: An Updated, Evidence-Based Review
2023, Seminars in Neurology
- 1
Participating centers (principal investigators of The Netherlands ALS Consortium): Academic Hospitals of Rotterdam (P.A. van Doorn and H.F.M. Busch), Utrecht (J.H.J. Wokke and F.G.I. Jennekens), Leyden (J.J.G.M. Verschuuren and A.R. Wintzen), Nijmegen (A. Keyser and G.W.A.M. Padberg), University of Amsterdam (M. de Visser and J.M.B.V. de Jong), Maastricht (C.J. Höweler and J.S.H. Vles), Groningen (A.E.J. de Jager and H.J.G.H. Oosterhuis), and of the Free University of Amsterdam (C.H. Polman and J.C. Koetsier), The Netherlands.